 This is a prospective, randomized, controlled, interventional pilot study analyzing both providers and patients perceptions and responses to the DNA Insight test. Twelve military health system primary care providers and 4 of each providers patients will be enrolled in the study. 12 providers and 48 patients total Each providers patients will be randomized into delayed treatment Group A or immediate treatment Group B at a 1:1 ratio. All patients receive the Pain Medication and Mental Health DNA InsightTM test intervention. Results for patients in Group A will be given to the provider with a 3 month delay. Those in the 3 month delay will serve as a comparison group for the period prior to receiving intervention. Results for patients in Group B will be given to the provider without delay, 2-3 weeks after saliva sample collection. The provider will use the results of the Pain Medication and Mental Health DNA InsightTM test to evaluate whether changes of medications are indicated based on the individual patients genetic profile. A measure of the providers certainty, confidence, satisfaction, perception of care and global impression of change will be assessed at baseline, prior to obtaining the test results, and after obtaining the test results, as outlined in the data collection section. Patients pain related self-reported outcomes, certainty, confidence and satisfaction will be assessed at baseline, prior to obtaining the DNA InsightTM test results, and after receipt and implementation of the test results, as described in the data collection section of the protocol. 